ACTA1 and Cirrhosis: All of the data demonstrated that the severity of cirrhosis was mitigated in animals administered a high-dose of GP; indeed, these animals had significantly increased bile flow, significantly smaller spleens and significantly decreased levels of α-SMA expression.